ABT FY 2013 Earnings Report — Abbott Laboratories Revenue & Financial Results | Market Cap Arena

Abbott LaboratoriesABT

FY 2013 Earnings

Reported February 21, 2014

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2013	Prior Q	FY 2012	QoQ Change	YoY Change
Revenue	$21.8B	—	$39.9B	—	-45.2%
Op. Income	$2.1B	—	$2.0B	—	6.9%
Gross Margin	45.1%	—	27.2%	—	17.9pp
Net Margin	11.8%	—	15.0%	—	-3.2pp
EPS (Diluted)	$1.64	—	$3.75	—	-56.3%
Free Cash Flow	$2.2B	—	$7.5B	—	-71.0%

Revenue Flow

Item	Amount
REVENUE	$21.8B
Cost of Revenue	$9.8B
GROSS PROFIT	$9.9B
R&D Expenses	$1.4B
Selling & Marketing	$0
General & Administrative	$6.9B
SG&A Expenses	$6.3B
Other Expenses	$0
Operating Expenses	$7.7B
Cost & Expenses	$17.5B
OPERATING INCOME	$2.1B
Interest Income	$67M
Interest Expense	$47M
Other Income/Expenses	-$105M
INCOME BEFORE TAX	$2.5B
Income Tax Expense	$138M
Net Income from Continuing Ops	$2.0B
Net Income from Discontinued Ops	$588M
Other Adjustments	$0
NET INCOME	$2.6B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$2.6B
D&A	$1.5B
EBIT	$2.1B
EBITDA	$3.6B
EPS	$2
EPS Diluted	$2

Income Statement

Item	Amount
REVENUE	$21.8B
Cost of Revenue	$9.8B
GROSS PROFIT	$9.9B
R&D Expenses	$1.4B
Selling & Marketing	$0
General & Administrative	$6.9B
SG&A Expenses	$6.3B
Other Expenses	$0
Operating Expenses	$7.7B
Cost & Expenses	$17.5B
OPERATING INCOME	$2.1B
Interest Income	$67M
Interest Expense	$47M
Other Income/Expenses	-$105M
INCOME BEFORE TAX	$2.5B
Income Tax Expense	$138M
Net Income from Continuing Ops	$2.0B
Net Income from Discontinued Ops	$588M
Other Adjustments	$0
NET INCOME	$2.6B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$2.6B
D&A	$1.5B
EBIT	$2.1B
EBITDA	$3.6B
EPS	$2
EPS Diluted	$2

Cash Flow Statement

Item	Amount
Net Income	$2.6B
Depreciation & Amortization	$1.7B
Stock-Based Compensation	$262M
Deferred Income Tax	$395M
Other Non-Cash Items	-$391M
Change in Working Capital	-$1.2B
OPERATING CASH FLOW	$3.3B
Capital Expenditure	-$1.1B
Acquisitions (Net)	-$580M
Purchases of Investments	-$10.1B
Sales/Maturities of Investments	$7.8B
Other Investing Activities	$21M
NET CASH FROM INVESTING	-$3.9B
Net Debt Issuance	$1.8B
Common Stock Repurchased	-$1.6B
Common Dividends Paid	-$882M
Other Financing Activities	-$6.0B
NET CASH FROM FINANCING	-$6.7B
FREE CASH FLOW	$2.2B
Net Change in Cash	-$7.3B

Balance Sheet

Item	Amount
Cash & Equivalents	$3.5B
Short-Term Investments	$4.6B
Net Receivables	$4.0B
Inventory	$2.7B
Other Current Assets	$4.5B
TOTAL CURRENT ASSETS	$19.2B
PP&E (Net)	$5.9B
Goodwill	$9.8B
Intangible Assets	$5.7B
Long-Term Investments	$119M
Tax Assets	$0
Other Non-Current Assets	$2.2B
TOTAL NON-CURRENT ASSETS	$23.7B
TOTAL ASSETS	$43.0B
Account Payables	$1.0B
Short-Term Debt	$3.2B
Deferred Revenue	$0
Other Current Liabilities	$4.2B
TOTAL CURRENT LIABILITIES	$9.5B
Long-Term Debt	$3.4B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$466M
Other Non-Current Liabilities	$4.3B
TOTAL NON-CURRENT LIABILITIES	$8.2B
TOTAL LIABILITIES	$17.7B
Common Stock	$12.0B
Additional Paid-In Capital	$0
Retained Earnings	$22.0B
Treasury Stock	-$6.8B
Accum. Other Comp. Income	-$2.0B
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$25.2B
Minority Interest	$96M
TOTAL EQUITY	$25.3B
TOTAL LIABILITIES & EQUITY	$43.0B
Total Debt	$6.6B
Net Debt	$3.1B